双重打击淋巴瘤诊疗的研究进展

Advances in diagnosis and treatment of double-hit lymphoma

双重打击淋巴瘤（DHL）是一种具有独特生物学特性及高度侵袭性的B细胞淋巴瘤。DHL在组织形态学上缺乏特异性，目前对其诊断仍依靠荧光原位杂交（FISH）技术检测MYC基因及BCL-2、-6基因重排。DHL患者的一般治疗方法包括常规化疗、新型药物治疗及骨髓移植等，但其总体预后均较差。此外，采用新型靶向药物或新型药物联合传统药物治疗DHL的疗效，均仍有待进一步研究证实。笔者拟就目前DHL的诊断、治疗、预后及新型药物的研究进展等方面进行综述。

Double-hit lymphoma （DHL） is a B cell lymphoma with unique biological characteristics and high invasiveness. DHL lacks specificity in histomorphology. At present, its diagnosis still relies on fluorescence in situ hybridization （FISH） to detect rearrangement of MYC gene, BCL-2 and BCL-6 gene.DHL patients are generally treated with conventional chemotherapy, new drug therapy, and bone marrow transplantation. The overall prognosises of patients with DHL wasere all poor. In addition, the efficacy of new targeted drugs or new drugs combined with traditional drugs in the treatment of DHL remains to be confirmed. In this article, the current research of diagnosis, treatment, prognosis and research progress of new drugs on DHL are summarized.